{"title":"依赖SHH/YAP通路的人组织细胞肉瘤类器官的建立。","authors":"Yusuke Yoshimura, Keiichi Yoshida, Yukiko Matsuoka, Satoru Sasagawa, Noriko Nagamine, Yoji Kukita, Ryota Miyamoto, Rie Suzuki, Hironari Tamiya, Shigeki Kakunaga, Toshinari Yagi, Takuya Terakawa, Yuma Tada, Takafumi Yokota, Jun Ishikawa, Sho Nakai, Yoshinori Imura, Seiji Okada, Ken-Ichi Yoshida, Satoshi Takenaka, Toru Wakamatsu","doi":"10.1007/s13577-025-01308-6","DOIUrl":null,"url":null,"abstract":"<p><p>Histiocytic sarcoma is an extremely rare and aggressive malignant neoplasm characterized by immunophenotypic features of mature histiocytes. The mechanisms underlying its malignant transformation remain poorly understood; consequently, the development of effective therapies remains limited. Resected histiocytic sarcoma specimens were cultured using a modified air-liquid interface organoid method, serially passaged, and xenografted into NOD-scid IL2Rgnull mice. Tumors formed by xenografted organoids retained histological and genetic similarities with the original tumor. Genomic analysis revealed the activation of the Sonic Hedgehog signaling pathway and amplification of Yes-associated protein 1, a key effector of the Hippo pathway. Accordingly, we evaluated the sensitivity of the organoids to the Sonic Hedgehog inhibitor vismodegib and Yes-associated protein 1 inhibitor verteporfin, both of which demonstrated potent in vitro antitumor activity in organoid cultures. This model offers a valuable preclinical platform for investigating the molecular pathology of this rare malignancy and accelerating the development of targeted therapies.</p>","PeriodicalId":49194,"journal":{"name":"Human Cell","volume":"38 6","pages":"175"},"PeriodicalIF":3.1000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Establishment of human histiocytic sarcoma organoids dependent on the SHH/YAP pathway.\",\"authors\":\"Yusuke Yoshimura, Keiichi Yoshida, Yukiko Matsuoka, Satoru Sasagawa, Noriko Nagamine, Yoji Kukita, Ryota Miyamoto, Rie Suzuki, Hironari Tamiya, Shigeki Kakunaga, Toshinari Yagi, Takuya Terakawa, Yuma Tada, Takafumi Yokota, Jun Ishikawa, Sho Nakai, Yoshinori Imura, Seiji Okada, Ken-Ichi Yoshida, Satoshi Takenaka, Toru Wakamatsu\",\"doi\":\"10.1007/s13577-025-01308-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Histiocytic sarcoma is an extremely rare and aggressive malignant neoplasm characterized by immunophenotypic features of mature histiocytes. The mechanisms underlying its malignant transformation remain poorly understood; consequently, the development of effective therapies remains limited. Resected histiocytic sarcoma specimens were cultured using a modified air-liquid interface organoid method, serially passaged, and xenografted into NOD-scid IL2Rgnull mice. Tumors formed by xenografted organoids retained histological and genetic similarities with the original tumor. Genomic analysis revealed the activation of the Sonic Hedgehog signaling pathway and amplification of Yes-associated protein 1, a key effector of the Hippo pathway. Accordingly, we evaluated the sensitivity of the organoids to the Sonic Hedgehog inhibitor vismodegib and Yes-associated protein 1 inhibitor verteporfin, both of which demonstrated potent in vitro antitumor activity in organoid cultures. This model offers a valuable preclinical platform for investigating the molecular pathology of this rare malignancy and accelerating the development of targeted therapies.</p>\",\"PeriodicalId\":49194,\"journal\":{\"name\":\"Human Cell\",\"volume\":\"38 6\",\"pages\":\"175\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Cell\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1007/s13577-025-01308-6\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Cell","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s13577-025-01308-6","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
组织细胞肉瘤是一种极其罕见的侵袭性恶性肿瘤,其特征是成熟组织细胞的免疫表型特征。其恶性转化的机制尚不清楚;因此,有效疗法的发展仍然有限。切除的组织细胞肉瘤标本采用改良的气液界面类器官法培养,连续传代,并移植到NOD-scid IL2Rgnull小鼠体内。由异种类器官移植形成的肿瘤与原肿瘤保留了组织学和遗传上的相似性。基因组分析显示Sonic Hedgehog信号通路被激活,并扩增了yes相关蛋白1 (Hippo通路的一个关键效应蛋白)。因此,我们评估了类器官对Sonic Hedgehog抑制剂vismodegib和yesassociated protein 1抑制剂verteporfin的敏感性,这两种药物在类器官培养中都显示出有效的体外抗肿瘤活性。该模型为研究这种罕见恶性肿瘤的分子病理学和加速靶向治疗的发展提供了一个有价值的临床前平台。
Establishment of human histiocytic sarcoma organoids dependent on the SHH/YAP pathway.
Histiocytic sarcoma is an extremely rare and aggressive malignant neoplasm characterized by immunophenotypic features of mature histiocytes. The mechanisms underlying its malignant transformation remain poorly understood; consequently, the development of effective therapies remains limited. Resected histiocytic sarcoma specimens were cultured using a modified air-liquid interface organoid method, serially passaged, and xenografted into NOD-scid IL2Rgnull mice. Tumors formed by xenografted organoids retained histological and genetic similarities with the original tumor. Genomic analysis revealed the activation of the Sonic Hedgehog signaling pathway and amplification of Yes-associated protein 1, a key effector of the Hippo pathway. Accordingly, we evaluated the sensitivity of the organoids to the Sonic Hedgehog inhibitor vismodegib and Yes-associated protein 1 inhibitor verteporfin, both of which demonstrated potent in vitro antitumor activity in organoid cultures. This model offers a valuable preclinical platform for investigating the molecular pathology of this rare malignancy and accelerating the development of targeted therapies.
期刊介绍:
Human Cell is the official English-language journal of the Japan Human Cell Society. The journal serves as a forum for international research on all aspects of the human cell, encompassing not only cell biology but also pathology, cytology, and oncology, including clinical oncology. Embryonic stem cells derived from animals, regenerative medicine using animal cells, and experimental animal models with implications for human diseases are covered as well.
Submissions in any of the following categories will be considered: Research Articles, Cell Lines, Rapid Communications, Reviews, and Letters to the Editor. A brief clinical case report focusing on cellular responses to pathological insults in human studies may also be submitted as a Letter to the Editor in a concise and short format.
Not only basic scientists but also gynecologists, oncologists, and other clinical scientists are welcome to submit work expressing new ideas or research using human cells.